NCT02691871 2016-02-25Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1 Unknown20 enrolled